Molecular Immunology2022,Vol.1452.DOI:10.1016/j.molimm.2022.03.001

Use of sulforaphane in COVID-19: Clinical trials are needed

Kow, Chia Siang Ramachandram, Dinesh Sangarran Hasan, Syed Shahzad
Molecular Immunology2022,Vol.1452.DOI:10.1016/j.molimm.2022.03.001

Use of sulforaphane in COVID-19: Clinical trials are needed

Kow, Chia Siang 1Ramachandram, Dinesh Sangarran 2Hasan, Syed Shahzad3
扫码查看

作者信息

  • 1. Sch Pharm,Int Med Univ
  • 2. Sch Pharm,Monash Univ Malaysia
  • 3. Sch Appl Sci,Univ Huddersfield
  • 折叠

Abstract

We read with interest the narrative review authored by Kiser et al. (2021), which discussed extensively the antioxidant effect and anti-inflammatory effect of sulforaphane, a dietary supplement found in high amounts in cruciferous vegetables that ais orally accessible and well-tolerated. Notably, in their review, the authors also discussed the potential use of sulforaphane in patients with coronavirus disease 2019 (COVID-19). Sulforaphane mediates the inhibitory effect on NLRP3 inflammasome activation and we believe that this could be the main mechanism where sulforaphane is useful for patients with COVID-19.

引用本文复制引用

出版年

2022
Molecular Immunology

Molecular Immunology

ISTP
ISSN:0161-5890
被引量3
参考文献量7
段落导航相关论文